FDA Approval of Tisagenlecleucel: Promise and Complexities of a $475 000 Cancer Drug.

In this article, the author reflects upon the FDA's approval of Tisagenlecleucel, a drug used to treat cancer. Topics discussed include how the drug has been approved to treat acute lymphoblastic leukemia, how a one-time infusion of the drug costs $475,000 and details relating to the drug's black box warning as its use can cause hypotension, multiorgan failure and even death. Details relating to revenue outlooks for pharmaceutical companies including Novartis and Gilead are also offered.